Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Mar 2020
Historique:
received: 02 12 2019
revised: 29 01 2020
accepted: 29 01 2020
pubmed: 18 2 2020
medline: 15 12 2020
entrez: 17 2 2020
Statut: ppublish

Résumé

Combretastatin A-4 (CA-4) is a natural anti-cancer agent isolated in 1989 from the African willow tree, Combretum caffrum. Due to its chemical simplicity, this (Z)-stilbene has been the subject of many structural modifications mainly to improve its chemical and metabolic stability. Beside a large number of synthetic analogues, isoCombretastatin A-4 (isoCA-4), has proved to be a solution of choice since this non-natural isomer of CA-4 is stable, easier to synthesize and has equivalent antitumor properties as CA-4. In this review, we will present the structure-activity relationships (SARs) around isoCA-4 since its discovery in 2007. In a first part, we will describe some alternatives to replace the phenol B-ring of isoCA-4, then we will focus on the variations made on the 1,1-ethylene double bond and then, we will evocate very recent exiting results concerning the possible replacements of the 3,4,5-trimethoxyphenyl A-ring of isoCA-4 by suitable heterocycles.

Identifiants

pubmed: 32061961
pii: S0223-5234(20)30077-5
doi: 10.1016/j.ejmech.2020.112110
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Stilbenes 0
Tubulin Modulators 0
fosbretabulin I5590ES2QZ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112110

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Abdallah Hamze (A)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France.

Mouad Alami (M)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France. Electronic address: mouad.alami@Universite-Paris-Saclay.fr.

Olivier Provot (O)

Université Paris-Saclay, CNRS, BioCIS, 92290, Châtenay-Malabry, France. Electronic address: olivier.provot@Universite-Paris-Saclay.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH